© 2017 Evestra, Inc.

Evestra Onkologia

Evestra Onkologia Sp. z o.o, located to Lodz, Poland is a wholly-owned subsidiary of Evestra, Inc. This subsidiary was launched in 2015 and includes a distinguished team with an impressive record in developing and commercializing innovative products for the treatment of various types of oncological indications, as well as other proliferative disease products.

The key mission of Evestra Onkologia is to engage in highly innovative Research and Development as it pertains to the development and commercialization of oncology and endometriosis assets in Poland and beyond within the EU. To accomplish the core mission, the Company has established a variety of fruitful collaborations with leading Polish research institutions and investigators in the oncology and gynecology areas, as well as for-profit CRO companies in Poland. These key partnerships and collaborations serve to enhance development and commercialization of Evestra Onkologia’s innovative assets.

Evestra Onkologia is proud to have received a major research and development grant. This $4.6 million project, co-financed by the European Union Regional Development Fund, will support development of EC313 as a drug designed to treat endometriosis.

Dr. Maciej Wierzbicki and an experienced R&D team in Lodz are excited to be working on the development of EC313.

For more information please refer to Evestra Onkologia´s website:   www.evestraonkologia.pl.